Hyaluronic Acid Combined with Serum Rich in Growth Factors in Corneal Epithelial Defects

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Apr 17

PMID 30987108

Citations 14

Authors

Carlota Suarez-Barrio

Jaime Etxebarria

Raquel Hernaez-Moya

Marina Del Val-Alonso

Maddalen Rodriguez-Astigarraga

Arantza Urkaregi

Vanesa Freire

Maria-Celia Morales

Juan Antonio Duran

Marta Vicario

Irene Molina

Rocio Herrero-Vanrell

Noelia Andollo

Affiliations

Soon will be listed here.

Abstract

The aim of this study is to assess if an adhesive biopolymer, sodium hyaluronate (NaHA), has synergistic effects with s-PRGF (a serum derived from plasma rich in growth factors and a blood derivative that has already shown efficacy in corneal epithelial wound healing), to reduce time of healing or posology. In vitro proliferation and migration studies, both in human corneal epithelial (HCE) cells and in rabbit primary corneal epithelial (RPCE) cultures, were carried out. In addition, we performed studies of corneal wound healing in vivo in rabbits treated with s-PRGF, NaHA, or the combination of both. We performed immunohistochemistry techniques (CK3, CK15, Ki67, ß4 integrin, ZO-1, α-SMA) in rabbit corneas 7 and 30 days after a surgically induced epithelial defect. In vitro results show that the combination of NaHA and s-PRGF offers the worst proliferation rates in both HCE and RPCE cells. Addition of NaHA to s-PRGF diminishes the re-epithelializing capability of s-PRGF. In vivo, all treatments, given twice a day, showed equivalent efficacy in corneal epithelial healing. We conclude that the combined use of s-PRGF and HaNA as an adhesive biopolymer does not improve the efficacy of s-PRGF alone in the wound healing of corneal epithelial defects.

Citing Articles

Exosomes derived from platelet-rich plasma present a novel potential in repairing knee articular cartilage defect combined with cyclic peptide-modified β-TCP scaffold.

Liu X, Chen R, Cui G, Feng R, Liu K J Orthop Surg Res. 2024; 19(1):718.

PMID: 39497084 PMC: 11533314. DOI: 10.1186/s13018-024-05202-z.

Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats.

McLaughlin P, Sassani J, Diaz D, Zagon I J Diabetes Clin Res. 2023; 5(1):1-10.

PMID: 37304310 PMC: 10254076. DOI: 10.33696/diabetes.4.054.

Hyaluronic acid hydrogels crosslinked via blue light-induced thiol-ene reaction for the treatment of rat corneal alkali burn.

Park S, Ha M, Kim E, Seo Y, Lee H, Myung D Regen Ther. 2022; 20:51-60.

PMID: 35402662 PMC: 8971597. DOI: 10.1016/j.reth.2022.03.005.

Prospects and Applications of Natural Blood-Derived Products in Regenerative Medicine.

Wessely-Szponder J, Zdziennicka J, Junkuszew A, Latalski M, Swieca M, Szponder T Int J Mol Sci. 2022; 23(1).

PMID: 35008900 PMC: 8745602. DOI: 10.3390/ijms23010472.

Tissue Engineering Meets Nanotechnology: Molecular Mechanism Modulations in Cornea Regeneration.

Mijanovic O, Pylaev T, Nikitkina A, Artyukhova M, Brankovic A, Peshkova M Micromachines (Basel). 2021; 12(11).

PMID: 34832752 PMC: 8618371. DOI: 10.3390/mi12111336.

References

Panda A, Pushker N, Bageshwar L . Lateral tarsorrhaphy: is it preferable to patching?. Cornea. 1999; 18(3):299-301. DOI: 10.1097/00003226-199905000-00010. View

Kruse F, Rohrschneider K, Volcker H . Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers. Ophthalmology. 1999; 106(8):1504-10; discussion 1511. DOI: 10.1016/S0161-6420(99)90444-X. View

Tsubota K, Goto E, Shimmura S, Shimazaki J . Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999; 106(10):1984-9. DOI: 10.1016/S0161-6420(99)90412-8. View

Rosenthal P, COTTER J, Baum J . Treatment of persistent corneal epithelial defect with extended wear of a fluid-ventilated gas-permeable scleral contact lens. Am J Ophthalmol. 2000; 130(1):33-41. DOI: 10.1016/s0002-9394(00)00379-2. View

DE CAMPOS A, Sanchez A, Alonso M . Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int J Pharm. 2001; 224(1-2):159-68. DOI: 10.1016/s0378-5173(01)00760-8. View

Calonge M . The treatment of dry eye. Surv Ophthalmol. 2001; 45 Suppl 2:S227-39. DOI: 10.1016/s0039-6257(00)00205-8. View

Aragona P, Papa V, Micali A, Santocono M, Milazzo G . Long term treatment with sodium hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye. Br J Ophthalmol. 2002; 86(2):181-4. PMC: 1771021. DOI: 10.1136/bjo.86.2.181. View

Debbasch C, De La Salle S, Brignole F, Rat P, Warnet J, Baudouin C . Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells. Invest Ophthalmol Vis Sci. 2002; 43(11):3409-15. View

Pastor J, Calonge M . Epidermal growth factor and corneal wound healing. A multicenter study. Cornea. 1992; 11(4):311-4. DOI: 10.1097/00003226-199207000-00007. View

10.

Gomes J, Amankwah R, Powell-Richards A, Dua H . Sodium hyaluronate (hyaluronic acid) promotes migration of human corneal epithelial cells in vitro. Br J Ophthalmol. 2004; 88(6):821-5. PMC: 1772195. DOI: 10.1136/bjo.2003.027573. View

11.

Geerling G, MacLennan S, Hartwig D . Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004; 88(11):1467-74. PMC: 1772389. DOI: 10.1136/bjo.2004.044347. View

12.

Klenkler B, Sheardown H . Growth factors in the anterior segment: role in tissue maintenance, wound healing and ocular pathology. Exp Eye Res. 2004; 79(5):677-88. DOI: 10.1016/j.exer.2004.07.008. View

13.

Seitz B, Gruterich M, Cursiefen C, Kruse F . [Conservative and surgical treatment of neurotrophic keratopathy]. Ophthalmologe. 2004; 102(1):15-26. DOI: 10.1007/s00347-004-1161-7. View

14.

Brignole F, Pisella P, Dupas B, Baeyens V, Baudouin C . Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. Graefes Arch Clin Exp Ophthalmol. 2005; 243(6):531-8. DOI: 10.1007/s00417-004-1040-6. View

15.

Schlotzer-Schrehardt U, Kruse F . Identification and characterization of limbal stem cells. Exp Eye Res. 2005; 81(3):247-64. DOI: 10.1016/j.exer.2005.02.016. View

16.

Scheibner K, Lutz M, Boodoo S, Fenton M, Powell J, Horton M . Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol. 2006; 177(2):1272-81. DOI: 10.4049/jimmunol.177.2.1272. View

17.

Yoshida S, Shimmura S, Kawakita T, Miyashita H, Den S, Shimazaki J . Cytokeratin 15 can be used to identify the limbal phenotype in normal and diseased ocular surfaces. Invest Ophthalmol Vis Sci. 2006; 47(11):4780-6. DOI: 10.1167/iovs.06-0574. View

18.

Alio J, Abad M, Artola A, Rodriguez-Prats J, Pastor S, Ruiz-Colecha J . Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. Ophthalmology. 2007; 114(7):1286-1293.e1. DOI: 10.1016/j.ophtha.2006.10.044. View

19.

Waddell D . Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. Drugs Aging. 2007; 24(8):629-42. DOI: 10.2165/00002512-200724080-00002. View

20.

Yamada N, Matsuda R, Morishige N, Yanai R, Chikama T, Nishida T . Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy. Br J Ophthalmol. 2008; 92(7):896-900. DOI: 10.1136/bjo.2007.130013. View